These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 31692478

  • 1. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F, Roche N, Belhassen M, Nolin M, Pegliasco H, Deslée G, Housset B, Devillier P, Van Ganse E.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [Abstract] [Full Text] [Related]

  • 2. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 3. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS, Landis SH, Wurst K, Le H.
    Respir Res; 2015 Nov 16; 16():141. PubMed ID: 26572740
    [Abstract] [Full Text] [Related]

  • 4. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():73-83. PubMed ID: 28053518
    [Abstract] [Full Text] [Related]

  • 5. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V, Sangiorgi D, Buda S, Degli Esposti L.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov 16; 11():2749-2755. PubMed ID: 27853362
    [Abstract] [Full Text] [Related]

  • 6. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS, DePietro M, McPheeters J, Fox KM.
    Ther Adv Respir Dis; 2018 Nov 16; 12():1753466618772750. PubMed ID: 29737943
    [Abstract] [Full Text] [Related]

  • 7. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH, Yang TM, Lin CM, Huang SY, Wen YW.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():2787-2793. PubMed ID: 29026296
    [Abstract] [Full Text] [Related]

  • 8. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
    Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 16; 13():2557-2568. PubMed ID: 30197512
    [Abstract] [Full Text] [Related]

  • 9. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS, Pascoe KC, Siddall J, Small M, Müllerová H.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 16; 14():2711-2723. PubMed ID: 31819403
    [Abstract] [Full Text] [Related]

  • 10. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T.
    J Comp Eff Res; 2019 Nov 16; 8(15):1299-1316. PubMed ID: 31559852
    [Abstract] [Full Text] [Related]

  • 11. Symptomatic burden of COPD for patients receiving dual or triple therapy.
    Chen S, Small M, Lindner L, Xu X.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 16; 13():1365-1376. PubMed ID: 29731624
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH, Dalal AA.
    Int J Chron Obstruct Pulmon Dis; 2012 Nov 16; 7():221-33. PubMed ID: 22500122
    [Abstract] [Full Text] [Related]

  • 13. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov 16; 11():2851-2858. PubMed ID: 27920512
    [Abstract] [Full Text] [Related]

  • 14. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K, Silva Miguel L, Hillas G, Borges M, Papageorgiou G, Viana D, Malhadeiro J, Soulard S.
    Ther Adv Respir Dis; 2020 Nov 16; 14():1753466620926802. PubMed ID: 32519591
    [No Abstract] [Full Text] [Related]

  • 15. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 16; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 18. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
    Calabria S, Ronconi G, Dondi L, Piccinni C, Pedrini A, Esposito I, Pistelli R, Martini N.
    Pulm Pharmacol Ther; 2020 Apr 16; 61():101904. PubMed ID: 32092473
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 16; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.